The FDA ™s emergency use authorization of Diagnostic Hybrids ™ H1N1 Influenza A Virus ID kit will allow access to a monoclonal antibody product with great potential for expediting patient care in a time when fast, accurate diagnosis of 2009 H1N1 infection is critical, said David R. Scholl, Ph.D., senior vice president, commercial operations & president of Diagnostic Hybrids. As we enter the main part of flu season in North America, we are proud to provide large and small laboratories alike with a cost-effective method for the detection of 2009 H1N1 infections.

The D3 Ultra H1N1 ID Kit is the first indirect fluorescent assay available on the market that specifically identifies the 2009 H1N1 influenza A virus from nasopharyngeal swabs, aspirates and washes. It complements the company ™s other respiratory testing technologies, which can detect the H1N1 virus as influenza A positive, but do not specifically identify the 2009 H1N1 influenza virus subtype.

SOURCE Quidel Corporation